SCOPUS 정보 검색 플랫폼

Annals of Hematology

Volumn 88, Issue 4, 2009, Pages 399-400

A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure

(1) Haslbauer, Ferdinand a

a Oncology Department (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; CD38 ANTIGEN; FAMCICLOVIR; FLUDARABINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ABSENCE OF SIDE EFFECTS; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIGEN EXPRESSION; B CELL LEUKEMIA; BACTERIAL INFECTION; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 13Q; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ECHOGRAPHY; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERURICEMIA; IMMUNOPHENOTYPING; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; LYMPHOCYTE COUNT; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SPLENOMEGALY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; KIDNEY FAILURE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; TREATMENT OUTCOME;

EID: 60749104420 PISSN: 09395555 EISSN: None Source Type: Journal
DOI: 10.1007/s00277-008-0630-5 Document Type: Letter

Times cited : (2)

References (5)

1
- 11144357712
- Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
- doi: 10.3816/CLM.2004.n.002
- Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 4:220-227. doi: 10.3816/ CLM.2004.n.002
- (2004) Clin Lymphoma , vol.4 , pp. 220-227
- Keating, M.¹ Coutré, S.² Rai, K.³ Osterborg, A.⁴ Faderl, S.⁵ Kennedy, B.⁶ Kipps, T.⁷ Bodey, G.⁸ Byrd, J.C.⁹ Rosen, S.¹⁰ Dearden, C.¹¹ Dyer, M.J.¹² Hillmen, P.¹³

2
- 0036683449
- Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
- doi: 10.1182/blood-2002-01-0159
- Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773. doi: 10.1182/blood-2002-01-0159
- (2002) Blood , vol.100 , pp. 768-773
- Lundin, J.¹ Kimby, E.² Björkholm, M.³ Broliden, P.A.⁴ Celsing, F.⁵ Hjalmar, V.⁶ Möllgård, L.⁷ Rebello, P.⁸ Hale, G.⁹ Waldmann, H.¹⁰ Mellstedt, H.¹¹ Osterborg, A.¹²

3
- 46749112012
- Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H Trial of the GCLLSG)
- Abstract
- Stilgenbauer S, Winkler D, Bühler A, Zenz T, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Trümper L, Söling U, Schlag R, Hallek M, Döhner H (2007) Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H Trial of the GCLLSG). Blood 110:ABstract 3120
- (2007) Blood , vol.110 , pp. 3120
- Stilgenbauer, S.¹ Winkler, D.² Bühler, A.³ Zenz, T.⁴ Groner, S.⁵ Busch, R.⁶ Hensel, M.⁷ Dührsen, U.⁸ Finke, J.⁹ Dreger, P.¹⁰ Jäger, U.¹¹ Lengfelder, E.¹² Trümper, L.¹³ Söling, U.¹⁴ Schlag, R.¹⁵ Hallek, M.¹⁶ Döhner, H.¹⁷

4
- 60749088086
- Subcutaneous alemtuzumab without dose escalation in patients with previously treated B-cell chronic lymphocytic leukaemia
- In: Geneva, June 10-13, Abstract
- Österborg A, Kimby E, Kennedy B, Strandberg M, Moreton P, Hillmen P (2004) Subcutaneous alemtuzumab without dose escalation in patients with previously treated B-cell chronic lymphocytic leukaemia. In: 9th Annual Congress European Hematology Association, Geneva, June 10-13, Abstract 881
- (2004) 9th Annual Congress European Hematology Association , pp. 881
- Österborg, A.¹ Kimby, E.² Kennedy, B.³ Strandberg, M.⁴ Moreton, P.⁵ Hillmen, P.⁶

5
- 60749114636
- Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study
- Abstract 2959
- Dyer MS, Buckby E, Fermahan P, Walewska R, Kennedy B (2005) Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1B15 study. Blood 106:Abstract 2959
- (2005) Blood , vol.106
- Dyer, M.S.¹ Buckby, E.² Fermahan, P.³ Walewska, R.⁴ Kennedy, B.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.